203 related articles for article (PubMed ID: 27143937)
1. Risk of adverse events with bevacizumab addition to therapy in advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Lai XX; Xu RA; Yu-Ping L; Yang H
Onco Targets Ther; 2016; 9():2421-8. PubMed ID: 27143937
[TBL] [Abstract][Full Text] [Related]
2. Adverse events risk associated with angiogenesis inhibitors addition to therapy in ovarian cancer: a meta-analysis of randomized controlled trials.
Liang XJ; Shen J
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(12):2701-9. PubMed ID: 27383326
[TBL] [Abstract][Full Text] [Related]
3. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials.
Ranpura V; Hapani S; Chuang J; Wu S
Acta Oncol; 2010 Apr; 49(3):287-97. PubMed ID: 20156114
[TBL] [Abstract][Full Text] [Related]
4. Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer: A meta-analysis.
Gu B; Gao W; Chu H; Gao J; Fu Z; Ding H; Lv J; Wu Q
Medicine (Baltimore); 2016 Nov; 95(48):e3752. PubMed ID: 27902583
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a meta-analysis.
Yang K; Wang YJ; Chen XR; Chen HN
Clin Drug Investig; 2010; 30(4):229-41. PubMed ID: 20225906
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
7. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis.
Nalluri SR; Chu D; Keresztes R; Zhu X; Wu S
JAMA; 2008 Nov; 300(19):2277-85. PubMed ID: 19017914
[TBL] [Abstract][Full Text] [Related]
8. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Hapani S; Wu S
JAMA; 2011 Feb; 305(5):487-94. PubMed ID: 21285426
[TBL] [Abstract][Full Text] [Related]
9. Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.
Cortes J; Calvo V; Ramírez-Merino N; O'Shaughnessy J; Brufsky A; Robert N; Vidal M; Muñoz E; Perez J; Dawood S; Saura C; Di Cosimo S; González-Martín A; Bellet M; Silva OE; Miles D; Llombart A; Baselga J
Ann Oncol; 2012 May; 23(5):1130-1137. PubMed ID: 21976387
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic therapy with anti-vascular endothelial growth factor modalities for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Brunetti M
Cochrane Database Syst Rev; 2012 Dec; 12():CD007419. PubMed ID: 23235642
[TBL] [Abstract][Full Text] [Related]
11. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.
Zhu X; Wu S; Dahut WL; Parikh CR
Am J Kidney Dis; 2007 Feb; 49(2):186-93. PubMed ID: 17261421
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.
Shin S; Noh Y
Ther Clin Risk Manag; 2018; 14():833-847. PubMed ID: 29765225
[TBL] [Abstract][Full Text] [Related]
13. Anti-vascular endothelial growth factor for diabetic macular oedema.
Virgili G; Parravano M; Menchini F; Evans JR
Cochrane Database Syst Rev; 2014 Oct; (10):CD007419. PubMed ID: 25342124
[TBL] [Abstract][Full Text] [Related]
14. Incidence and risk of thromboembolism associated with bevacizumab in patients with non-small cell lung carcinoma.
Li LJ; Chen DF; Wu GF; Guan WJ; Zhu Z; Liu YQ; Gao GY; Qin YY; Zhong NS
J Thorac Dis; 2018 Aug; 10(8):5010-5022. PubMed ID: 30233875
[TBL] [Abstract][Full Text] [Related]
15. Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials.
Raphael J; Chan K; Karim S; Kerbel R; Lam H; Santos KD; Saluja R; Verma S
Clin Lung Cancer; 2017 Jul; 18(4):345-353.e5. PubMed ID: 28188101
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab increases the risk of infections in cancer patients: A systematic review and pooled analysis of 41 randomized controlled trials.
Qi WX; Fu S; Zhang Q; Guo XM
Crit Rev Oncol Hematol; 2015 Jun; 94(3):323-36. PubMed ID: 25749417
[TBL] [Abstract][Full Text] [Related]
17. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis.
Hapani S; Chu D; Wu S
Lancet Oncol; 2009 Jun; 10(6):559-68. PubMed ID: 19482548
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients.
Totzeck M; Mincu RI; Rassaf T
J Am Heart Assoc; 2017 Aug; 6(8):. PubMed ID: 28862931
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Bevacizumab Biosimilars Compared With Reference Biologics in Advanced Non-small Cell Lung Cancer or Metastatic Colorectal Cancer Patients: A Network Meta-Analysis.
Xu X; Zhang S; Xu T; Zhan M; Chen C; Zhang C
Front Pharmacol; 2022; 13():880090. PubMed ID: 35865968
[No Abstract] [Full Text] [Related]
20. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups.
Qi WX; Shen Z; Tang LN; Yao Y
Eur J Clin Pharmacol; 2014 Aug; 70(8):893-906. PubMed ID: 24858820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
